Pharmacokinetics of favipiravir in adults with mild COVID-19 in Thailand

2

3

4

5

1

- Weerawat Manosuthi^{a,*}, Ing-orn Prasanchaimontri^{b,*}, Suvimol Niyomnaitham^{c,d}, Rujipas Sirijatuphat^e,
- Lantharita Charoenpong^a, Katherine Copeland^f, Tim R. Cressey^{g,h}, Phongpan Mokmuedⁱ,

and Kulkanya Chokephaibulkit^{d,k#}

6 ^aBamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health, 7 Nonthaburi, Thailand; ^bBureau of Drug and Narcotic, Department of Medical Sciences, Ministry of Public 8 Health, Nonthaburi, Thailand; ^cDepartment of Pharmacology, Faculty of Medicine Siriraj Hospital, 9 Mahidol University, Thailand; ^dSiriraj Institute of Clinical Research (SICRES), Mahidol University, 10 Thailand: ^eDepartment of Medicine, Faculty of Medicine Sirirai Hospital, Mahidol University, Thailand 11 ^fMahidol University International College, Salaya, Nakhon Pathom, Thailand; ^gAMS-IRD collaboration, 12 Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, 13 Thailand; ^hDepartment of Molecular & Clinical Pharmacology, University of Liverpool, UK; ⁱDivision of 14 Genomics Medicine and Innovation Support, Department of Medical Sciences, Ministry of Public Health, 15 Nonthaburi, Thailand; ^jDepartment of Paediatrics, Faculty of Medicine Siriraj Hospital, Mahidol 16 University, Thailand

17

#Corresponding author: Kulkanya Chokephaibulkit, MD, Professor of Paediatrics, Department of
Paediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Siriraj Institute of Clinical
Research (SICRES), 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand Tel: (+66) 2-4141899;
Fax: (+66) 2-4128243, E-mail: kulkanya.cho@mahidol.ac.th

22 *Weerawat Manosuthi and Ing-orn Prasanchaimontri equally contributed to the research work.

23

- 24 Running title: Favipiravir PK in Thai patients with mild COVID-19
- 25

26 Abstract

We assessed the pharmacokinetics of favipiravir (FPV) in adults with symptomatic SARS-CoV-2 infection without pneumonia in Thailand. FPV dosing was 1800 mg twice-daily on day 1, then 800 mg twice-daily for 14 days. Eight subjects (7 female), median (range) age 39 (19-53) years and BMI 27.9 (18.0-33.6) were included. Inter-subject variability was high but all achieved minimum plasma concentrations (C_{min}) above EC₅₀ (9.7 mg/L). FPV was well tolerated; 1 subject stopped prematurely due to rash.

33

34 Key words: Favipiravir, COVID-19, Thai adults, pharmacokinetic

35 Introduction

Favipiravir (FPV) is a pyrazine carboxamide derivative that has recently been repurposed to treat mild-tomoderate cases of COVID-19 (1,2). Preliminary studies have demonstrated its capacity to competitively
inhibit the replication of SARS-CoV-2 *in-vitro* (3-5) and possibly control viral progression, promote viral
clearance, as well as improve clinical outcomes *in-vivo* (5, 6).

40

41 FPV is a prodrug (T-705) that is intracellularly metabolised through ribosylation into its active form (T-42 705-RTP). Viral RNA-dependant RNA polymerase (RdRp) recognises this active form as a purine-base 43 analogue and incorporates it into nascent viral RNA whereby it exerts its antiviral activity (1, 2, 5-7). FPV 44 is primarily metabolised by hepatic aldehyde oxidase, and partially by xanthine oxidase, to a hydroxylated 45 inactive metabolite (T-705M1) that is excreted in the urine (4, 7, 8).

46

The recommended FPV dosing regimen for the treatment of COVID-19 in Thailand is 1800 mg twicedaily for the first day, and then 800 mg twice-daily for a total duration of 5-14 days (5). While numerous studies have explored the clinical effects of such dosing regimens, few studies have assessed its pharmacokinetics, and no studies have been performed in the Thai population (9, 10). It is important to characterise the impact of regional and ethnic difference on the pharmacokinetic profile to ensure optimised dosing for the viral variants circulating in the region (9). Our aim was to investigate the pharmacokinetics of FPV in mild cases of COVID-19 without pneumonia within a Thai population.

54 Methods

55 Here we report the results of a pharmacokinetic sub-study of FPV nested within a prospective randomized 56 clinical trial of adults with symptomatic SARS-CoV-2 infection without pneumonia. Enrolled subjects 57 were randomised to receive supportive symptomatic care with or without FPV. The FPV dosing regimen 58 was 1800 mg twice-daily on the first day, and then 800 mg twice-daily for 5-14 days or until viral 59 clearance. Subjects receiving other medication with reported antiviral activity against SARS-CoV-2 were 60 excluded. Pharmacokinetic assessments were proposed to subjects receiving FPV. This study was 61 approved by the Siriraj Institutional Review Board (approval no. Si 434/2020) and registered at 62 Thaiclinicaltrials.org (No. TCTR20200514001).

63

64 Pharmacokinetic Assessments

Blood samples were drawn pre-dose, and 1-hour after FPV administration on days 1, 2, 3, 4, 5, 7, and 14.
Plasma proteins were precipitated with ethanol (1:4) and the supernatant stored at -20°C until analyses. T705 and T-705M1 concentrations were quantified using a validated high performance liquid
chromatography-UV assay, with a calibration range of 0.1 to 50 mg/L.

69

70 **Results**

Eight patients (7 females) were included, median (range) age was 39 (19-53) years, BMI was 27.9 (18.0-33.6), 3 patients (37.5%) had underlying diseases, and none developed pneumonia or experienced disease progression . Subjects No. 1 and 3-5 were treated with FPV for 14 days, while subjects No. 6-8 were treated for 7 days. Subject No. 2 dropped out on day 4 of treatment due to an erythematous skin rash. Individual plasma concentrations versus time curves for T-705 and T-705M1 after the first dose of FPV are shown in Figure 1. Initial pre-dose T-705 concentrations for subjects No. 4 and 5 indicated they had received a dose of FPV before PK assessment.

78

Minimum plasma concentration levels (C_{min}) of T-705 were above the reported EC₅₀ for SARS-COV-2 (9.7 mg/L) for all subjects, except for subject No. 6 after their first dose (8.6 mg/L). The C_{min} and C_{max} of T-705 ranged from 12.1-132.2 mg/L and 14.5-201.2 mg/L, respectively, and was found to decreased overtime. C_{min} and C_{max} of T-705M1 ranged from 1.6-6.7 mg/L and 2.0-24.8 mg/L, respectively, but remained relatively stable overtime. Inter-subject variability was high, with a coefficient of variation (CV) of 37-74% for T-705 and 12-62% for T-705M1.

85

86 Discussion

We evaluated FPV plasma concentrations in adults with mild COVID-19 that did not require oxygen
supplementation. FPV plasma concentrations with the currently recommended FPV dosing regimen in
Thailand [1800 mg twice-daily (9 tablets per dose) on day 1, followed by 800 mg twice-daily (4 tablets
per dose) until the end of treatment] provided concentrations above the reported EC₅₀.

91

92 Favipiravir loading doses studied have ranged from 400-6000 mg, split into 2-3 doses per day (11). A 93 1600 mg twice-daily dose on day 1, followed by 600 mg twice-daily on days 2-5 achieve trough 94 concentrations between 20-60 mg/L after 12 hours (12). The large loading dose of FPV used in our study 95 was reported to rapidly reach minimum target concentrations of 40-80 mg/L, and the large difference 96 between its EC₅₀ of 61.88 μ M (9.72 mg/L) and half-cytotoxic concentration (CC₅₀) of >400 μ M (62.83 97 mg/L) provides a wide therapeutic range (3,5,11).

98

Some controversy remains regarding the EC_{50} of FPV for SARS-CoV-2. Some studies have reported similar values to our study (9,12); while others failed to identify inhibition of SARS-CoV-2 below 100 μ M (15.71 mg/L) *in-vitro* (15), or found only 50% virus inhibition at this concentration (16). All of the adults in our study achieved T-705 concentrations above our target EC_{50} of 9.7 mg/L. The high interpatient variability observed is likely a result of the multiple intrinsic and external factors that can impact the pharmacokinetic profile of FPV (9). For example, the potential impact of pharmacogenomics

105 on FPV clearance in different populations is highlighted by the significantly higher FPV plasma 106 concentrations in Japanese populations compared to patients in the United States (7), and decreased 107 exposures in African and American patients compared to Chinese patients (18). While the T-705 plasma 108 concentration varied between patients, the overall concentrations observed in our study remained within 109 target ranges. Favipiravir was well tolerated, expect for one patient who experienced a cutaneous rash and 110 discontinued treatment. Of note, this participant had relatively high FPV concentrations (99.7-201.2 111 mg/L) and low BMI (18.3). None of the patients' clinical outcomes deteriorated during FPV treatment 112 but a larger population of mild COVID-19 cases is needed to confirm this observation.

113

A limitation of this study was the ability to associate clinical or virologic outcomes with FPV drug exposure. Overall, this study provides novel data on the pharmacokinetics of FPV and its metabolite in adults with symptomatic SARS-CoV-2 infection without pneumonia and can help to guide dosing recommendations.

118

119 Acknowledgements

We would like to thank the National Centre for Global Health and Medicine, Japan and FUJIFILM
Toyama Chemical Co., Ltd. We are also thankful for the support from the National Institute of Health,
Thailand.

123

124 Data availability statement

125 Data are available upon request.

126

```
127 Funding
```

This work was supported by the National Research Council of Thailand (Grant Number: 63-088) and the
Siriraj Research and Development Fund, Faculty of Medicine Siriraj Hospital, Mahidol University (Grant
Number: (IO) R016434001).

131

132 Transparency declarations

133 None to declare

134 References

- Seneviratne SL, Abeysuriya V, De Mel S, De Zoysa I, Niloofa R. 2020. Favipiravir in COVID-19.
 IJPSAT 19:143–145.
- Furuta Y, Komeno T, Nakamura T. 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral
 RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci* 93:449–463.
- Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir
 and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 30:269-271.
- 4. Eroglu E, Toprak C. 2021. Overview of Favipiravir and Remdesivir treatment for COVID-19. *Int J Pharm Sci Res* 12:1950–7.
- Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. 2021. Role of
 favipiravir in the treatment of COVID-19. *Int J Infect Dis* 102:501–508.
- 146 6. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M,
- 147 Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T,
- 148 Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H,
- 149 Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki
- 150 T, Nakayama E, Taniguchi S, Lim C, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y,
- 151 Kondo M. 2020. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir
- 152 Therapy in Hospitalized Patients with COVID-19. *Antimicrob Agents Chemother* 64.
- 1537. Du YX, Chen XP. Favipiravir: 2020. Pharmacokinetics and Concerns About Clinical Trials for 2019-
- 154 nCoV Infection. *Clin Pharmacol Ther* 108:242–247.
- FUJIFILM Toyama Chemical Co. L. Notice of The New Drug Application Approval of "AVIGAN® Tablet 200mg" in Japan for the Anti-influenza Virus Drug.
- 157 <u>https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw.</u>
- 158 9. Ison MG, Scheetz MH. 2021. Understanding the pharmacokinetics of Favipiravir: Implications for
- treatment of influenza and COVID-19. *EBioMedicine* 63:103204.

- 160 10. Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, Muroi N, Fukushima S, Tomii K,
- 161 Hashida T. 2021. Population pharmacokinetics of favipiravir in patients with COVID 19. CPT

162 *Pharmacometrics Syst Pharmacol* 10:1161–1170.

- 11. Pilkington V, Pepperrell T, Hill A. 2020. A review of the safety of favipiravir a potential treatment
 in the COVID-19 pandemic? *J Virus Erad* 6:45–51.
- 165 12. Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, Muroi N, Tomii K, Hashida T. 2020.
- Pharmacokinetics of Favipiravir in Critically III Patients With COVID 19. *Clin Transl Sci* 13:880–
 885.
- 168 13. Manabe T, Kambayashi D, Akatsu H, Kudo K. 2021. Favipiravir for the treatment of patients with
 COVID-19: a systematic review and meta-analysis. *BMC Infect Dis* 21:489.
- 170 14. Department of Disease Control. Guidelines for clinical practice, diagnosis, treatment and prevention
- 171 of healthcare-associated infection in response to patients with COVID-19 infection.
- 172 <u>https://ddc.moph.go.th/viralpneumonia/eng/file/guidelines/g_CPG.pdf</u>.
- 173 15. Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K, Chu D, Chan M, Cheung P, Huang X,
- Peiris M, Yen H. 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2
 replication in vitro. *Antiviral Res* 178:104786.
- 176 16. Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, Luo R, Yang X, He L, Lu X, Zhao Q, Liang T, Qiu Y.
- 177 2021. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in
 178 COVID-19 Patients: An Exploratory Randomized, Controlled Trial. *Eur J Pharm Sci* 157:105631.
- 179 17. Takahashi T, Luzum JA, Nicol MR, Jacobson PA. 2020. Pharmacogenomics of COVID-19
 180 therapies. *NPJ Genom Med* 5:35.
- 181 18. Pertinez H, Rajoli RKR, Khoo SH, Owen A. 2021. Pharmacokinetic modelling to estimate
- 182 intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-
- **183** 2. *J Antimicrob Chemother* 76:2121–2128.

- 184 19. Kaur R, Charan J, Dutta S, Sharma P, Bhardwaj P, Sharma P, Lugova H, Krishnapillai A, Islam S,
- 185 Haque M, Misra S. 2020. Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug
- 186 Events Reported in the WHO Database. *Infect Drug Resist* 13:4427–4438.

187 Figure Legend

188




Figure 1. Individual plasma concentration of T-705 and T-705M1 for (a) Subject No. 1, female with BMI of 30.1 within age range of 30-35 years, (b) Subject No. 2, female with BMI of 18.3 within age range of 35-40 years, (c) Subject No. 3, female with BMI of 33.6 within age range of 40-45 years, (d) Subject No. 4, female with BMI of 30 within age range of 25-30 years, (e) Subject No. 5, female with BMI of 27.5 within age range of 45-50 years, (f) Subject No. 6, male with BMI of 26.9 within age range of 50-55 years, (g) Subject No. 7, female with BMI of 28.2 within age range of 35-40 years, and (h) Subject No. 8, female with BMI of 18 within age range of 15-20 years. The dash line represents an EC₅₀ of 9.7 mg/L.